| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10215306 | Brain and Development | 2018 | 8 Pages |
Abstract
PGD2 might help explain the progression and symptomatic presentations (e.g., ambulatory difficulty) associated with DMD, suggesting it as a useful pathological marker and use of a selective PGD2 inhibitor as a potential treatment modality.
Related Topics
Life Sciences
Neuroscience
Developmental Neuroscience
Authors
Eri Takeshita, Hirofumi Komaki, Hisateru Tachimori, Kazuhisa Miyoshi, Ikuo Yamamiya, Yuko Shimizu-Motohashi, Akihiko Ishiyama, Takashi Saito, Eiji Nakagawa, Kenji Sugai, Masayuki Sasaki,